Back to Search
Start Over
[Rituximab (MabThera): a new therapy for ANCA vasculitis].
- Source :
-
Revue medicale de Liege [Rev Med Liege] 2015 Feb; Vol. 70 (2), pp. 92-100. - Publication Year :
- 2015
-
Abstract
- Three recently published randomized studies have demonstrated the efficacy of rituximab in the induction and maintenance therapy of ANCA vasculitis. This is a major advance since these types of vasculitis entail a high morbity and mortality.
- Subjects :
- Adult
Aged
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis epidemiology
Female
Humans
Male
Middle Aged
Morbidity
Randomized Controlled Trials as Topic
Remission Induction
Rituximab
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy
Antibodies, Monoclonal, Murine-Derived therapeutic use
Subjects
Details
- Language :
- French
- ISSN :
- 0370-629X
- Volume :
- 70
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Revue medicale de Liege
- Publication Type :
- Academic Journal
- Accession number :
- 26011994